Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: A meta-analysis of randomized controlled trials

Zhi Hua Zhang, Hai Yun Liu, Sergio E. Hernandez-Da Mota, Mario R. Romano, Khalil G. Falavarjani, Hamid Ahmadieh, Xun Xu, Kun Liu

Research output: Contribution to journalArticle

Abstract

Purpose: To compare safety and functional outcomes of vitrectomy with or without preoperative intravitreal bevacizumab (IVB) for proliferative diabetic retinopathy (PDR). Design: A meta-analysis of randomized controlled trials. Methods: PubMed, Medline, EMBASE, and Cochrane Controlled Trials Register were searched to identify potentially relevant randomized controlled trials. A total of 394 participants with 414 eyes in 8 trials were analyzed using RevMan 5.1 software. The primary measures included intraoperative bleeding, total surgical time, and early and late recurrent hemorrhage. Results: Vitrectomy with IVB pretreatment achieved shorter overall surgical time (mean difference = -26.89 minutes, 95% confidence interval [CI] -31.38 to -22.39, P

Original languageEnglish
JournalAmerican Journal of Ophthalmology
Volume156
Issue number1
DOIs
Publication statusPublished - Jul 2013

    Fingerprint

ASJC Scopus subject areas

  • Ophthalmology

Cite this